Noteworthy Different paths for gp120 trials

When the government decided in June 1994 not to fund large-scale trials of gp120 vaccines for AIDS, it wasn't clear how or when such trials might go forward.

The National Institute of Allergy and Infectious Diseases decided to wait to run 30,000-patient trials until there was compelling evidence suggesting that the vaccines would be likely to be highly effective, or until another promising vaccine was ready for trials (see BioCentury, June 20, 1994).